VERONA PHARMA P/S (NASDAQ:VRNA) – Equities research analysts at SunTrust Banks issued their Q1 2019 earnings per share (EPS) estimates for VERONA PHARMA P/S in a research note issued on Wednesday, February 27th. SunTrust Banks analyst J. Lee anticipates that the company will post earnings of ($0.76) per share for the quarter. SunTrust Banks also issued estimates for VERONA PHARMA P/S’s Q2 2019 earnings at ($0.89) EPS, Q3 2019 earnings at ($0.66) EPS, Q4 2019 earnings at ($0.64) EPS, FY2019 earnings at ($2.86) EPS and FY2020 earnings at ($2.40) EPS.
Get VERONA PHARMA P/S alerts:A number of other equities analysts also recently weighed in on the stock. Wedbush reissued a “buy” rating on shares of VERONA PHARMA P/S in a report on Monday, January 14th. ValuEngine raised shares of VERONA PHARMA P/S from a “hold” rating to a “buy” rating in a report on Wednesday, November 21st. Finally, Zacks Investment Research raised shares of VERONA PHARMA P/S from a “hold” rating to a “strong-buy” rating and set a $14.00 price target on the stock in a report on Saturday, November 10th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. VERONA PHARMA P/S currently has a consensus rating of “Buy” and an average price target of $33.25.
Shares of NASDAQ:VRNA opened at $5.83 on Monday. The stock has a market capitalization of $76.75 million, a P/E ratio of -2.89 and a beta of -1.26. VERONA PHARMA P/S has a fifty-two week low of $5.52 and a fifty-two week high of $25.55.
Several large investors have recently modified their holdings of the stock. Foresite Capital Management IV LLC purchased a new position in shares of VERONA PHARMA P/S in the 3rd quarter worth about $104,000. Wedbush Securities Inc. purchased a new position in shares of VERONA PHARMA P/S in the 4th quarter worth about $127,000. Finally, Aisling Capital Management LP purchased a new position in shares of VERONA PHARMA P/S in the 4th quarter worth about $4,281,000. 59.72% of the stock is currently owned by institutional investors.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Read More: What is an SEC Filing?
No comments:
Post a Comment